Patents by Inventor Amanda Huynh
Amanda Huynh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951006Abstract: A prosthetic heart valve has a plurality of valve leaflets that control directional flow of blood through a heart and a stent structure having a plurality of commissure posts supporting the valve leaflets. The stent structure has a covering over the plurality of commissure posts and has a sewing ring at an inflow end of the stent structure. Each of the plurality of commissure posts has a tip and a suture loop is attached to the covering at a location adjacent to or on the tip of the commissure post. Each suture loop provides a passage for a suture to pass through between the covering and the suture loop.Type: GrantFiled: January 4, 2023Date of Patent: April 9, 2024Assignee: EDWARDS LIFESCIENCES CORPORATIONInventors: Da-Yu Chang, Amy E. Munnelly, Van Huynh, Avina Gupta, Brian S. Conklin, Sooji Van Echten, Kurt Kelly Reed, Amanda Grace Sall
-
Publication number: 20240068971Abstract: A method for quantifying amounts of per- and poly-fluoroalkyl substances (PFAS) may use a PFAS detection system comprising a working electrode and one or more processors. The working electrode may have a polymer layer disposed on its surface that comprises a plurality of affinity sites for detecting a plurality of PFAS molecules. Each of the plurality affinity sites may have been created using a template PFAS. The method may comprise detecting, at the working electrode, a plurality PFAS molecules that have bonded to one or more of the plurality of affinity sites; and determining, by the one or more processors and based on the detected plurality of PFAS molecules that are bonded to the one or more affinity sites, a concentration of PFAS in an environment.Type: ApplicationFiled: August 25, 2023Publication date: February 29, 2024Applicant: The MITRE CorporationInventors: Jamie Amanda GROVE, Kathy T. HUYNH, Emiko ZUMBRO, Joseph John Patrick ROBERTS, Sean Mitchell OLIVER, Lindsey Jordan GOODNIGHT, Nathan Isaac WALTON
-
Patent number: 11458212Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 9, 2019Date of Patent: October 4, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of the University of /ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Patent number: 11414455Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: October 5, 2020Date of Patent: August 16, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDAInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20210230219Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: October 5, 2020Publication date: July 29, 2021Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Patent number: 10793595Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: October 3, 2018Date of Patent: October 6, 2020Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDAInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20200164093Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: ApplicationFiled: September 9, 2019Publication date: May 28, 2020Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of The University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Patent number: 10406248Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 5, 2012Date of Patent: September 10, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board Of Regents on Behalf of the University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20190263857Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: October 3, 2018Publication date: August 29, 2019Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Patent number: 10118942Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: March 25, 2016Date of Patent: November 6, 2018Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., The Arizona Board of Regents on behalf of the University of Arizona, University of South FloridaInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20180051055Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: March 25, 2016Publication date: February 22, 2018Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20140161725Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: ApplicationFiled: September 5, 2012Publication date: June 12, 2014Applicants: Arizona Board Of Regents on Behalf of the University of Arizona, H. Lee Moffitt Cancer Center and Research Instutute, Inc.Inventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner